These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 32584791)

  • 1. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer.
    Ugolini A; Tyurin VA; Tyurina YY; Tcyganov EN; Donthireddy L; Kagan VE; Gabrilovich DI; Veglia F
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer.
    Veglia F; Tyurin VA; Mohammadyani D; Blasi M; Duperret EK; Donthireddy L; Hashimoto A; Kapralov A; Amoscato A; Angelini R; Patel S; Alicea-Torres K; Weiner D; Murphy ME; Klein-Seetharaman J; Celis E; Kagan VE; Gabrilovich DI
    Nat Commun; 2017 Dec; 8(1):2122. PubMed ID: 29242535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
    Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
    Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide mediated inhibition of antigen presentation from DCs to CD4
    Markowitz J; Wang J; Vangundy Z; You J; Yildiz V; Yu L; Foote IP; Branson OE; Stiff AR; Brooks TR; Biesiadecki B; Olencki T; Tridandapani S; Freitas MA; Papenfuss T; Phelps MA; Carson WE
    Sci Rep; 2017 Nov; 7(1):15424. PubMed ID: 29133913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
    Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
    Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
    Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
    Front Immunol; 2021; 12():803014. PubMed ID: 35116033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function.
    Odobasic D; Kitching AR; Yang Y; O'Sullivan KM; Muljadi RC; Edgtton KL; Tan DS; Summers SA; Morand EF; Holdsworth SR
    Blood; 2013 May; 121(20):4195-204. PubMed ID: 23509155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer.
    Ramakrishnan R; Tyurin VA; Veglia F; Condamine T; Amoscato A; Mohammadyani D; Johnson JJ; Zhang LM; Klein-Seetharaman J; Celis E; Kagan VE; Gabrilovich DI
    J Immunol; 2014 Mar; 192(6):2920-31. PubMed ID: 24554775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy.
    Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I
    Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualization and quantification of
    Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
    Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD205
    Fu C; Fu Z; Jiang C; Xia C; Zhang Y; Gu X; Zheng K; Zhou D; Tang S; Lyu S; Ma S
    Cancer Sci; 2021 Mar; 112(3):1011-1025. PubMed ID: 33368883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells.
    Cioca DP; Deak E; Cioca F; Paunescu V
    J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion.
    DeVito NC; Plebanek MP; Theivanthiran B; Hanks BA
    Front Immunol; 2019; 10():2876. PubMed ID: 31921140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.